SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 6.1% – Should You Sell?

Posted by Brenda Bartman on May 21st, 2026

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report)’s share price dropped 6.1% during mid-day trading on Thursday . The stock traded as low as $8.41 and last traded at $8.4270. Approximately 3,462,138 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 7,707,157 shares. The stock had previously closed at $8.97.

Analyst Upgrades and Downgrades

SLS has been the subject of several recent research reports. Maxim Group increased their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $10.00.

Get Our Latest Report on SLS

SELLAS Life Sciences Group Stock Down 18.7%

The firm has a market capitalization of $1.36 billion, a PE ratio of -31.39 and a beta of 2.24. The firm’s 50 day moving average price is $5.20 and its two-hundred day moving average price is $3.87.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC purchased a new position in shares of SELLAS Life Sciences Group in the fourth quarter valued at $26,000. California State Teachers Retirement System boosted its stake in SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after acquiring an additional 1,709 shares during the last quarter. Beacon Pointe Advisors LLC bought a new position in SELLAS Life Sciences Group during the 4th quarter valued at $38,000. Concurrent Investment Advisors LLC bought a new position in SELLAS Life Sciences Group during the 4th quarter valued at $38,000. Finally, Money Concepts Capital Corp bought a new position in SELLAS Life Sciences Group during the 4th quarter valued at $40,000. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

About SELLAS Life Sciences Group

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.